Lurasidone moves forward in Canada as submission accepted
This article was originally published in Scrip
The regulatory authorities in Canada have accepted for review Dainippon Sumitomo Pharma's (DSP) lurasidone, taking the novel atypical antipsychotic a step closer to what looks likely to become its second market after the US.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.